# Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study

> **NCT01411150** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 38 (actual)

## Conditions studied

- Huntington's Disease

## Interventions

- **DRUG:** Creatine Monohydrate

## Key facts

- **NCT ID:** NCT01411150
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2014-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01411150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01411150, "Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01411150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*